Logo image of IGMS

IGM BIOSCIENCES INC (IGMS) Stock Fundamental Analysis

NASDAQ:IGMS - Nasdaq - US4495851085 - Common Stock - Currency: USD

1.62  +0.05 (+3.18%)

Fundamental Rating

3

Taking everything into account, IGMS scores 3 out of 10 in our fundamental rating. IGMS was compared to 572 industry peers in the Biotechnology industry. While IGMS seems to be doing ok healthwise, there are quite some concerns on its profitability. IGMS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IGMS had negative earnings in the past year.
IGMS had a negative operating cash flow in the past year.
In the past 5 years IGMS always reported negative net income.
IGMS had a negative operating cash flow in each of the past 5 years.
IGMS Yearly Net Income VS EBIT VS OCF VS FCFIGMS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M -250M

1.2 Ratios

Looking at the Return On Assets, with a value of -72.20%, IGMS is doing worse than 67.08% of the companies in the same industry.
With a Return On Equity value of -278.47%, IGMS is not doing good in the industry: 73.63% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -72.2%
ROE -278.47%
ROIC N/A
ROA(3y)-52.22%
ROA(5y)-38.61%
ROE(3y)-88.55%
ROE(5y)-60.98%
ROIC(3y)N/A
ROIC(5y)N/A
IGMS Yearly ROA, ROE, ROICIGMS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K -15K

1.3 Margins

IGMS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IGMS Yearly Profit, Operating, Gross MarginsIGMS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K -20K

More info and screens

6

2. Health

2.1 Basic Checks

IGMS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IGMS has more shares outstanding
Compared to 5 years ago, IGMS has more shares outstanding
IGMS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IGMS Yearly Shares OutstandingIGMS Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
IGMS Yearly Total Debt VS Total AssetsIGMS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -5.91, we must say that IGMS is in the distress zone and has some risk of bankruptcy.
IGMS's Altman-Z score of -5.91 is on the low side compared to the rest of the industry. IGMS is outperformed by 66.02% of its industry peers.
IGMS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.91
ROIC/WACCN/A
WACC10.71%
IGMS Yearly LT Debt VS Equity VS FCFIGMS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M -200M 300M

2.3 Liquidity

A Current Ratio of 5.22 indicates that IGMS has no problem at all paying its short term obligations.
IGMS has a Current ratio (5.22) which is comparable to the rest of the industry.
A Quick Ratio of 5.22 indicates that IGMS has no problem at all paying its short term obligations.
IGMS has a Quick ratio (5.22) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.22
Quick Ratio 5.22
IGMS Yearly Current Assets VS Current LiabilitesIGMS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 27.05% over the past year.
The Revenue has grown by 57.73% in the past year. This is a very strong growth!
EPS 1Y (TTM)27.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.88%
Revenue 1Y (TTM)57.73%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1.38%

3.2 Future

IGMS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.46% yearly.
Based on estimates for the next years, IGMS will show a very strong growth in Revenue. The Revenue will grow by 80.30% on average per year.
EPS Next Y27.97%
EPS Next 2Y33.36%
EPS Next 3Y21.41%
EPS Next 5Y12.46%
Revenue Next Year13.48%
Revenue Next 2Y59.85%
Revenue Next 3Y66.34%
Revenue Next 5Y80.3%

3.3 Evolution

IGMS Yearly Revenue VS EstimatesIGMS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
IGMS Yearly EPS VS EstimatesIGMS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -1 -2 -3 -4 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IGMS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IGMS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IGMS Price Earnings VS Forward Price EarningsIGMS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IGMS Per share dataIGMS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as IGMS's earnings are expected to grow with 21.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.36%
EPS Next 3Y21.41%

More info and screens

0

5. Dividend

5.1 Amount

IGMS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IGM BIOSCIENCES INC

NASDAQ:IGMS (2/5/2025, 2:58:48 PM)

1.62

+0.05 (+3.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-08 2024-11-08/bmo
Earnings (Next)N/A N/A
Inst Owners66.31%
Inst Owner Change0.05%
Ins Owners4.36%
Ins Owner Change3.19%
Market Cap96.33M
Analysts78.82
Price Target5.1 (214.81%)
Short Float %9.01%
Short Ratio3.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-986.91%
Min EPS beat(2)-1950.05%
Max EPS beat(2)-23.77%
EPS beat(4)2
Avg EPS beat(4)-491.9%
Min EPS beat(4)-1950.05%
Max EPS beat(4)4.11%
EPS beat(8)6
Avg EPS beat(8)-242.33%
EPS beat(12)9
Avg EPS beat(12)-163.03%
EPS beat(16)13
Avg EPS beat(16)-120.79%
Revenue beat(2)1
Avg Revenue beat(2)-4.21%
Min Revenue beat(2)-97.74%
Max Revenue beat(2)89.31%
Revenue beat(4)1
Avg Revenue beat(4)-13.34%
Min Revenue beat(4)-97.74%
Max Revenue beat(4)89.31%
Revenue beat(8)2
Avg Revenue beat(8)-23.17%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-74.65%
PT rev (3m)-74.23%
EPS NQ rev (1m)2.73%
EPS NQ rev (3m)6.71%
EPS NY rev (1m)-1.6%
EPS NY rev (3m)-9.68%
Revenue NQ rev (1m)28.2%
Revenue NQ rev (3m)14.75%
Revenue NY rev (1m)2.66%
Revenue NY rev (3m)-68.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 33.01
P/FCF N/A
P/OCF N/A
P/B 1.22
P/tB 1.22
EV/EBITDA N/A
EPS(TTM)-3.64
EYN/A
EPS(NY)-1.07
Fwd EYN/A
FCF(TTM)-2.9
FCFYN/A
OCF(TTM)-2.79
OCFYN/A
SpS0.05
BVpS1.33
TBVpS1.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -72.2%
ROE -278.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.22%
ROA(5y)-38.61%
ROE(3y)-88.55%
ROE(5y)-60.98%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 72.08%
Cap/Sales 220.73%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.22
Quick Ratio 5.22
Altman-Z -5.91
F-Score4
WACC10.71%
ROIC/WACCN/A
Cap/Depr(3y)204.35%
Cap/Depr(5y)540.42%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.88%
EPS Next Y27.97%
EPS Next 2Y33.36%
EPS Next 3Y21.41%
EPS Next 5Y12.46%
Revenue 1Y (TTM)57.73%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1.38%
Revenue Next Year13.48%
Revenue Next 2Y59.85%
Revenue Next 3Y66.34%
Revenue Next 5Y80.3%
EBIT growth 1Y13.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.88%
EBIT Next 3Y21.16%
EBIT Next 5YN/A
FCF growth 1Y-1274.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4951.28%
OCF growth 3YN/A
OCF growth 5YN/A